HUTCHMED (China) (HKG:0013) reported an attributable net income of $37.7 million in 2024, down from $100.8 million a year earlier.
Earnings per share were $0.04, a decline from $0.12 in the same period last year, according to a Wednesday filing with the Hong Kong bourse.
Revenue dropped to $630.2 million from $838.0 million the previous year.
Looking ahead, the biotech firm expects to generate a consolidated revenue of $350 million to $450 million for its oncology and immunology business.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.